Sino Biopharmaceutical (OTCMKTS:SBMFF) Reaches New 52-Week High - Here's Why

Key Points

• Sino Biopharmaceutical shares reached a new 52-week high at $1.16 during trading, marking a significant increase from its previous closing price of $0.99.
• The company operates as a research and development pharmaceutical conglomerate in China, focusing on various therapeutic areas including oncology, liver disease, and respiratory medicines.
• Recent performance metrics include a 50-day moving average of $0.89 and a 200-day moving average of $0.64, indicating positive momentum for the stock.

Sino Biopharmaceutical (OTCMKTS:SBMFF - ) shares reached a new 52-week high during trading on Monday . The stock traded as high as $1.16 and last traded at $1.16, with a volume of 1000 shares traded. The stock had previously closed at $0.99.

Sino Biopharmaceutical Stock Performance

The company has a 50 day moving average of $0.89 and a two-hundred day moving average of $0.64.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.